ATOS — ATOSSA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1488039 ·
Last close
$2.07
Market Cap
$20.65M
52W High
$6.18
52W Low
$1.70
ADV30
154,775
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,870,000 | -9,589,000 | 37,943,000 | 31,718,000 | 7,457,000 |
| Dec 2025 | 0 | — | -11,436,000 | -10,937,000 | 47,608,000 | 41,299,000 | 8,255,000 |
| Sep 2025 | 0 | — | -9,251,000 | -8,692,000 | 58,012,000 | 51,845,000 | 8,225,000 |
| Jun 2025 | 0 | — | -9,040,000 | -8,423,000 | 64,515,000 | 57,857,000 | 6,820,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,762,000
Investing CF
$-23,000
Financing CF
$0
CapEx
$-33,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.75
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-246,562,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-37,141,000
Pretax Income TTM
$-34,770,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,141,000 | -34,770,000 | 47,608,000 | 8,255,000 | — | -29,762,000 |
| Dec 2024 | 0 | -27,621,000 | -25,504,000 | 76,444,000 | 4,967,000 | — | -21,030,000 |
| Dec 2023 | 0 | -31,377,000 | -30,094,000 | 96,252,000 | 5,236,000 | — | -20,941,000 |
| Dec 2022 | 0 | -27,691,000 | -26,960,000 | 123,532,000 | 5,568,000 | — | -20,760,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.38
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.00 · spot: $2.07 · call volume: 41 · put volume: 10
Expected Move to 2026-08-21:
±$0.57
(27.54%) —
implied range
$1.50 –
$2.64
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLRB | Cellectar Biosciences, Inc. | $20.54M | $2.57 | — |
| NEUP | Neuphoria Therapeutics Inc. | $20.97M | $3.88 | — |
| LGVN | Longeveron Inc. | $21.15M | $0.70 | — |
| SKYE | Skye Bioscience, Inc. | $19.98M | $0.57 | — |
| TVRD | Tvardi Therapeutics, Inc. | $19.70M | $2.10 | — |
News headlines (Yahoo Finance, 1h cache)
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
2026-07-28 12:30 · Yahoo
Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs
2026-07-23 16:59 · Yahoo
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
2026-07-21 12:30 · Yahoo
ATOS: Raises up to $16.5 Million in Registered Direct Offering
2026-07-01 13:08 · Yahoo
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-12 21:30 · Yahoo
Top Midday Decliners
2026-06-11 17:47 · Yahoo
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-11 12:00 · Yahoo
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment
2026-06-10 16:51 · Yahoo
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics
2026-06-01 09:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.